twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel Chronic Kidney Disease Treatment Candidates March 4, 2021 Press Release Both TXR-1208 and TXR-1210 demonstrated significant decrease in kidney fibrosis and inflammation compared to TGFbeta mAb, the standard metric for positive efficacy. READ MORE
